Overview

Effect of KYG0395 on Primary Dysmenorrhea

Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to further assess the efficacy, safety and dose-response of KYG0395 in the treatment of primary dysmenorrhea.
Phase:
Phase 2
Details
Lead Sponsor:
Jiangsu Kanion Pharmaceutical Co., Ltd